| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America.
|
Clin Infect Dis
|
2009
|
3.52
|
|
2
|
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
|
Ann Intern Med
|
2014
|
3.48
|
|
3
|
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
|
J Am Coll Cardiol
|
2008
|
3.36
|
|
4
|
Antiretroviral therapies in women after single-dose nevirapine exposure.
|
N Engl J Med
|
2010
|
3.14
|
|
5
|
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study.
|
AIDS
|
2009
|
3.12
|
|
6
|
Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.
|
Clin Infect Dis
|
2003
|
3.07
|
|
7
|
Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection.
|
J Infect Dis
|
2012
|
2.64
|
|
8
|
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.
|
Circulation
|
2008
|
2.64
|
|
9
|
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary.
|
Circulation
|
2008
|
2.17
|
|
10
|
Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.
|
Clin Infect Dis
|
2004
|
2.17
|
|
11
|
Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion.
|
J Infect Dis
|
2003
|
2.04
|
|
12
|
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.
|
J Acquir Immune Defic Syndr
|
2002
|
1.98
|
|
13
|
Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy.
|
Clin Infect Dis
|
2004
|
1.54
|
|
14
|
Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa.
|
J Acquir Immune Defic Syndr
|
2008
|
1.46
|
|
15
|
Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine.
|
Proc Natl Acad Sci U S A
|
2011
|
1.42
|
|
16
|
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
|
AIDS
|
2012
|
1.35
|
|
17
|
Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.
|
Expert Opin Drug Metab Toxicol
|
2006
|
1.29
|
|
18
|
Mönckeberg sclerosis revisited: a clarification of the histologic definition of Mönckeberg sclerosis.
|
Arch Pathol Lab Med
|
2008
|
1.25
|
|
19
|
Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection.
|
AIDS
|
2013
|
1.23
|
|
20
|
Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort.
|
AIDS
|
2013
|
1.21
|
|
21
|
A biochemical fluorometric method for assessing the oxidative properties of HDL.
|
J Lipid Res
|
2011
|
1.17
|
|
22
|
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
|
J Infect Dis
|
2012
|
1.17
|
|
23
|
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome.
|
Clin Infect Dis
|
2003
|
1.16
|
|
24
|
Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study.
|
AIDS Care
|
2011
|
1.13
|
|
25
|
Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362.
|
AIDS Care
|
2011
|
1.13
|
|
26
|
Metabolic disease in HIV infection.
|
Lancet Infect Dis
|
2013
|
1.11
|
|
27
|
Calcification of the internal elastic lamina of coronary arteries.
|
Mod Pathol
|
2008
|
1.06
|
|
28
|
Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness.
|
AIDS
|
2010
|
1.06
|
|
29
|
Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals.
|
J Acquir Immune Defic Syndr
|
2013
|
1.05
|
|
30
|
A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.
|
AIDS
|
2015
|
1.05
|
|
31
|
The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients.
|
Antivir Ther
|
2004
|
1.02
|
|
32
|
Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women.
|
HIV Clin Trials
|
2007
|
1.01
|
|
33
|
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.
|
Clin Infect Dis
|
2009
|
0.96
|
|
34
|
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
|
Antimicrob Agents Chemother
|
2011
|
0.96
|
|
35
|
Determinants of participation in HIV clinical trials: the importance of patients' trust in their provider.
|
HIV Clin Trials
|
2009
|
0.95
|
|
36
|
Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.
|
J Clin Pharmacol
|
2011
|
0.95
|
|
37
|
The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
|
PLoS One
|
2012
|
0.95
|
|
38
|
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.
|
AIDS Patient Care STDS
|
2012
|
0.94
|
|
39
|
Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy.
|
J Clin Lipidol
|
2008
|
0.94
|
|
40
|
Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil.
|
Int J STD AIDS
|
2006
|
0.93
|
|
41
|
HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL.
|
Lipids Health Dis
|
2011
|
0.92
|
|
42
|
Clinical practice. Postexposure prophylaxis for HIV infection.
|
N Engl J Med
|
2009
|
0.92
|
|
43
|
Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women.
|
Clin Infect Dis
|
2007
|
0.91
|
|
44
|
Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in Acquired Immunodeficiency Syndrome.
|
Clin Infect Dis
|
2002
|
0.91
|
|
45
|
A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.
|
Antivir Ther
|
2003
|
0.90
|
|
46
|
Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults.
|
Lipids Health Dis
|
2013
|
0.89
|
|
47
|
Availability of HIV postexposure prophylaxis services in Los Angeles County.
|
Clin Infect Dis
|
2009
|
0.89
|
|
48
|
Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy.
|
Clin Infect Dis
|
2002
|
0.88
|
|
49
|
A pilot study of telmisartan for visceral adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial.
|
PLoS One
|
2013
|
0.87
|
|
50
|
Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.
|
AIDS
|
2010
|
0.86
|
|
51
|
Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccination.
|
J Virol
|
2008
|
0.86
|
|
52
|
Complications of HIV disease and antiretroviral therapy.
|
Top HIV Med
|
2006
|
0.85
|
|
53
|
Participation of women in HIV clinical trials: the IPEC-FIOCRUZ experience.
|
HIV AIDS (Auckl)
|
2011
|
0.85
|
|
54
|
Maternal outcomes after HAART for the prevention of mother-to-child transmission in HIV-infected women in Brazil.
|
Antivir Ther
|
2011
|
0.85
|
|
55
|
Coronary atherosclerotic lesions in human immunodeficiency virus-infected patients: a histopathologic study.
|
Cardiovasc Pathol
|
2008
|
0.85
|
|
56
|
Atherosclerotic oxalosis in coronary arteries.
|
Cardiovasc Pathol
|
2007
|
0.84
|
|
57
|
A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team.
|
J Infect Dis
|
2003
|
0.84
|
|
58
|
Moderate prevalence of transmitted drug resistance mutations among antiretroviral-naive HIV-infected pregnant women in Rio de Janeiro, Brazil.
|
AIDS Res Hum Retroviruses
|
2013
|
0.83
|
|
59
|
Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients.
|
Curr HIV/AIDS Rep
|
2005
|
0.83
|
|
60
|
Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
|
Arch Intern Med
|
2005
|
0.82
|
|
61
|
Complications of HIV infection and antiretroviral therapy.
|
Top HIV Med
|
2003
|
0.82
|
|
62
|
Complications of HIV disease and antiretroviral therapy.
|
Top Antivir Med
|
2011
|
0.81
|
|
63
|
Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study.
|
AIDS Res Hum Retroviruses
|
2013
|
0.81
|
|
64
|
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
|
AIDS
|
2015
|
0.81
|
|
65
|
Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE.
|
J Natl Med Assoc
|
2012
|
0.80
|
|
66
|
Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks.
|
AIDS
|
2015
|
0.80
|
|
67
|
Management of antiretroviral treatment-related complications.
|
Infect Dis Clin North Am
|
2007
|
0.80
|
|
68
|
Switching antiretroviral therapy to minimize metabolic complications.
|
HIV Ther
|
2010
|
0.80
|
|
69
|
Complications of HIV disease and antiretroviral therapy.
|
Top Antivir Med
|
2012
|
0.79
|
|
70
|
The safety of antiretroviral drugs.
|
Expert Opin Drug Saf
|
2008
|
0.79
|
|
71
|
HIV and atherosclerosis: moving from associations to mechanisms and interventions.
|
Ann Intern Med
|
2014
|
0.78
|
|
72
|
Complications of HIV disease and antiretroviral treatment.
|
Top HIV Med
|
2010
|
0.78
|
|
73
|
CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy.
|
Top Antivir Med
|
2013
|
0.78
|
|
74
|
Getting smarter--the toxicity of undertreated HIV infection.
|
N Engl J Med
|
2006
|
0.78
|
|
75
|
Risk of myocardial infarction and nucleoside analogues.
|
Lancet
|
2008
|
0.78
|
|
76
|
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Los Angeles County.
|
J Med Virol
|
2012
|
0.78
|
|
77
|
Sex Differences in HIV: Natural History, Pharmacokinetics, and Drug Toxicity.
|
Curr Infect Dis Rep
|
2005
|
0.77
|
|
78
|
Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection.
|
AIDS
|
2016
|
0.76
|
|
79
|
Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery.
|
J Acquir Immune Defic Syndr
|
2013
|
0.75
|
|
80
|
Predictors of impaired HDL function in HIV-1 infected compared to uninfected individuals.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
81
|
Response to: 'carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected patients'.
|
AIDS
|
2006
|
0.75
|
|
82
|
Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.
|
HIV Clin Trials
|
2015
|
0.75
|
|
83
|
Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals.
|
J Acquir Immune Defic Syndr
|
2014
|
0.75
|
|
84
|
Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
85
|
Antiretroviral initiation is associated with increased skeletal muscle area and fat content.
|
AIDS
|
2017
|
0.75
|